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Edited by Hans-Diezer KlenkAbstract We have evaluated antisense design and eﬃcacy of
locked nucleic acid (LNA) and DNA oligonucleotide (ON)
mix-mers targeting the conserved HIV-1 dimerization initiation
site (DIS). LNA is a high aﬃnity nucleotide analog, nuclease
resistant and elicits minimal toxicity. We show that inclusion
of LNA bases in antisense ONs augments the interference of
HIV-1 genome dimerization. We also demonstrate the concomi-
tant RNase H activation by six consecutive DNA bases in an
LNA/DNA mix-mer. We show ON uptake via receptor-medi-
ated transfection of a human T-cell line in which the mix-mers
subsequently inhibit replication of a clinical HIV-1 isolate. Thus,
the technique of LNA/DNA mix-mer antisense ONs targeting
the conserved HIV-1 DIS region may provide a strategy to pre-
vent HIV-1 assembly in the clinic.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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initiation site1. Introduction
Antisense oligonucleotides (ONs) have become a major tool
for functional genomics and there are many compounds in clin-
ical trials for a variety of human disorders [1]. One antisense
ON (Vitravene, Isis Pharmaceuticals, Carlsbad) has been ap-
proved for the clinic to inhibit cytomegalovirus. The antisense
ON recognizes its target by Watson-Crick base-pairing. The
inhibitory functions of antisense ONs are believed to be degra-
dation of the target RNA by RNase H, steric hindrance of the
translation machinery or prevention of other protein interac-
tions with the target RNA. RNase H is a cellular enzyme that
cleaves the RNA strand in a DNA/RNA hybrid [2,3].
For antisense applications, increased ON stability towards
nuclease degradation is important. Other desired properties
are high aﬃnity for the target, RNase H activation, and low
toxicity along with good solubility and uptake. A promising
and recent technology is the development of locked nucleic
acid (LNA, Fig. 1A) [4,5]. LNA shows minimal toxicity, en-*Corresponding author. Fax: +46 8 32 39 50.
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degradation [6,7]. LNA alone cannot activate RNase H, but in
a mix-mer combination with DNA increased RNase H activa-
tion can be achieved [7–10]. LNA mix-mers have very high po-
tency compared to other antisense chemistries and their
downregulating capacity also close in on that of siRNA [11].
We have applied a LNA/DNAmix-mer technology on a well-
conserved target in HIV-1, the dimerization initiation site (DIS)
[12,13]. TheHIVgenome is a homo-dimer of two senseRNAsin-
gle strands. The DIS is a stem loop structure with six self-com-
plementary nucleotides at the top (Fig. 1B, bold). There are
two major motifs in HIV-1; GUGCAC in subtypes A and C,
and GCGCGC in subtypes B and D [14,15] (see also current
alignments www.hiv.lanl.gov base 881–887). The loop is located
between the primer binding site and the splice donor site at the
end of the long terminal repeat (LTR) [16] and is involved in
the dimerization of the HIV-1 genome, packaging and proviral
synthesis [17–21]. TheHIV-1 subtypeAmotif is a good antisense
target in in vitro cell free systemwhere theHIV-1 genome dimer-
ization is inhibited byDIS targetingONs. It has been shown that
a 9-merRNAON is a good inhibitor, whereas the corresponding
DNAON does not aﬀect the dimerization [22,23]. These studies
also indicate that sense ONs work as competitive inhibitors to
this self-complimentary target. Here, we aim at increasing the
potency of the DIS-targeting ONs by exchanging DNA nucleo-
tides for high aﬃnity, nuclease resistance LNA in the DNA se-
quence creating LNA/DNA mix-mers.
We demonstrate that a mix-mer design can enhance the
HIV-1 inhibiting properties. In vitro, the LNA/DNA mix-mers
enhance the inhibition of HIV-1 genome dimerization and acti-
vate RNase H when the mix-mer has a DNA stretch of at least
six bases. We subsequently show good uptake of the LNA/
DNA mix-mers in a T-cell line and that they can inhibit repli-
cation of a clinical HIV-1 isolate.2. Materials and methods
2.1. Antisense oligonucleotides
All ONs used in this study are listed in Table 1. LNA/DNA mix-
mers were synthesized by Exiqon A/S (Copenhagen, Denmark) and
Proligo (Boulder, CO) under license from Exiqon A/S. Regular
DNA oligonucleotides were synthesized by ThermoHybaid (Ulm, Ger-
many). The ONs cover the HIV-1 subtype A DIS loop; 9-mers (DNA,
RNA, LNA and LNA/DNA mix-mers) and 18-mers (LNA/DNA mix-
mers with either 3 0 or 5 0 DNA tails).blished by Elsevier B.V. All rights reserved.
Fig. 1. (A) Locked nucleic acid (LNA) structure. (B) HIV-1 subtype A
dimerization initiation site (DIS). The six self-complementary bases are
marked in bold.
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Virus was multiplied in the Jurkat-Tat T-cell line [24,25], cultured in
RPMI-1640 with Glutamax I, 10% fetal bovine serum, 100 U/ml pen-
icillin, 100 lg/ml streptomycin and 0.29 mg/ml L-glutamine (LifeTech-
nologies, Sweden). The virus stock has 200 TCID50 on Jurkat-Tat
cells. The HIV strain used was a clinical subtype A designated #2102
(GenBank Accession No. AY817688). The virus was isolated on hu-
man PBL, ampliﬁed on PBMC according to the standard protocol.
2.3. Plasmid construction
pDIS2102 was constructed by RT-PCR ampliﬁcation of the ﬁrst 620
bases of the #2102 genome. The ampliﬁcate was ligated into pGem-T
(Promega, WI) downstream the T7 promoter. RNA for the reverse
transcriptase reaction was isolated from the #2102 viral supernatants
[26]. Primers for the PCR ampliﬁcation were 5 0-atatatgcatgctct-
ctcttgttagac-30 260 nt upstream DIS including an SphI site for direc-
tional cloning and 5 0-tgtcttttacctctatccgttgatg-3 0 360 nt downstream
DIS, corresponding to the region 1–615 of HIV-1 MAL described pre-
viously [27]. The cloned fragment from #2102 was sequenced to con-
ﬁrm the DIS region.
2.4. In vitro transcribed RNA and puriﬁcation
pDIS2102 was linearized with NotI and transcribed with T7 RNA
polymerase (Promega) generating a 630 nucleotide long transcript.
The transcribed product was puriﬁed on an agarose gel, the appropri-
ate band was excised and electro-eluted into 7.5 M ammonium acetate,
precipitated by ethanol, washed and re-suspended in nuclease free
water.Table 1
Oligonucleotides used in this study
HIV-1 subtype A, DIS loop (reversed):
Name Length
asDIS 1 9 nt
asDIS 2 9 nt
asDIS 3 9 nt
asDIS 4 9 nt
asDIS 5 9 nt
sDIS 6 9 nt
asDIS 7 mm 18 nt
asDIS 8 18 nt
asDIS 9 18 nt
sDIS 10 18 nt
sDIS 11 18 nt
as: antisense, s: sense, mm: mismatch control. Upper case bold: LNA, lower2.5. In vitro dimerization
The dimerization was performed as described previously [22,23]. In
vitro transcribed RNA was denatured at 96 C for 2 min, put on ice
and mixed with dimerization buﬀer (5·: 250 mM sodium cacodylate,
1.5 lM KCl and 25 mM MgCl2) and ON. The ﬁnal RNA concentra-
tion was 100–200 nM and ON concentration 1–2 lM, a molar ratio of
1:10. The mix was incubated at 37 C for 30 min and analyzed on a
1.2% agarose gel in TBM5 buﬀer (45 mM Tris borate, pH 8.3, 5 mM
MgOAc2) containing ethidium bromide. The separation was per-
formed at +4 C. The gel bands were quantiﬁed with GelDoc and
QuantityOne software (BioRad, CA).
2.6. RNase H activation
100 lg RNA (ﬁnal concentration 20 nM) was mixed with antisense
ON to a ﬁnal concentration of 200 nM, 2.5 U rRNasin (Promega),
RNase H buﬀer and 2.5 U RNase H (Fermentas AB, Vilnius, Lithua-
nia), and incubated at 37 C for 30 min. The RNA was analyzed on a
1.5% glyoxal denaturing agarose gel (Northern Max Gly kit, Ambion,
Huntingdon, UK), stained with SYBR gold (Molecular Probes, Lei-
den, The Netherlands) and documented with GelDoc and Quantity
One software (BioRad).
2.7. Receptor-mediated transfection
Transferrin linked to polyethyleneimine (PEI) [28,29], sold as Duo-
Fect from Qbiogene (IIkirch, France), was used to transfect Jurkat-
Tat cells. Jurkat-Tat cells were kept in exponential phase and split the
day before transfection into medium with 50 lM deferrioxamine but
without antibiotics. At the day of transfection, the cells were seeded in
ﬂat bottom 96-well plates, 45 000 cells per well in 130 ll mediumwithout
antibiotics and deferrioxamine. A N/P (nitrogen/phosphate) ratio (see
Duofect protocol, Qbiogene) of 4.8 was used, since it gave the highest
frequency of transfected cells (data not shown). 1.9 ll of 50 lMantisense
ON stock was mixed with 40 ll HBS (20 mM HEPES, pH 7.3 and 150
lM NaCl). 0.17–0.49 ll Duofect was added to another 40 ll of HBS
(volume depending on weight of the ON; 0.17 ll for 9-mers and 0.34
ll for 18-mers to keep a N/P ratio of 4.8). The two solutions were com-
bined and incubated at room temperature for 20–30min and then added
to the cells. Transfectionmixwas prepared for four wells and 20 ll of the
mix was used per well (ﬁnal ON concentration 160 nM).
Uptake of antisense ONs into the Jurkat-Tat cell line was conﬁrmed
by transfection of a FITC labeled 16 nucleotides long LNA/phosp-
horothioate mix-mer. The cells were subsequently analyzed by ﬂuores-
cence microscopy and digital camera operated by OpenLab software
(Improvision, Coventry, UK).
2.8. Inhibition of HIV replication
Cells were transfected with the LNA/DNA mix-mers in 96 wells the
day prior to infection (see transfection above). 100 ll transfected cell
suspension was transferred to a new 96 well U-bottom plate and each
well was infected with 100 ll of undiluted virus supernatant (200
TCID50). At day one post infection (PI), cells were spun down3 0-agcggagaacgac gucguucggcuc-5 0
Sequence
5 0-ugugcaccu-3 0
5 0-tgtgcacct-3 0
5 0-TgtgcacCT-3 0
5 0-TGTgcACCT-3 0
5 0-TGTGCACCT-3 0
5 0-AGGTgcACA-3 0
5 0-TGGtcACATccgcaagcc-30
5 0-TGTgcACCTcagcaagcc-3 0
5 0-ctcttgctgTGTgcACCT-3 0
5 0-AGGTgcACAcagcaagag-3 0
5 0-ggcttgctgAGGTgcACA-3 0
case: DNA, lower case italics: RNA, underlined: mismatch.
Fig. 2. Assay schemes and 9-mer performance. (A) Schematic of HIV-1 dimerization and appearance of dimer and monomer on a gel. (B) Inhibition
of in vitro dimerization by LNA/DNA mix-mers. In vitro transcribed HIV DIS RNA has been allowed to dimerize in the absence or presence of
oligonucleotides. Dimers and monomers are separated by gel electrophoresis and the bands are quantiﬁed and plotted as a ratio of the amount of
dimer to the total amount of dimer and monomer together. The ratio has been normalized to the ratio where no oligonucleotide is present. Mean and
standard deviation are from two to three replicates (\P < 0.05, \\P < 0.01 and \\\P < 0.001, as compared to DNA ON asDIS2). (C) Schematic of
RNase H activation. (D) RNase H activation by LNA/DNAmix-mers. In vitro transcribed HIV RNA (630 nucleotides) has been subjected to RNase
H digestion in the absence or presence of oligonucleotides. The digested/undigested RNA has been separated by gel electrophoresis. The full-length
transcript is 630 nucleotides long (no ON), cut transcript at target site generates two fragments, 260 nt and 370 nt long. asDIS 2 also shows full-length
undigested transcript as with no ON.
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four PI, 100 ll of supernatant was removed and 100 ll fresh medium
was added. Supernatants were harvested on day seven PI. The
amount of HIV in the supernatants was quantiﬁed by p24 ELISA
and reverse transcriptase activity assay (Lenti-RT kit, CavidiTech,
Uppsala, Sweden).3. Results
3.1. Dimerization inhibition and RNase H activation by 9-mer
ONs
The inhibition of HIV dimerization by nine nucleotides long
mix-mer ONs shows improvement by exchanging DNA for
LNA. A 630 nucleotide in vitro transcribed stretch of the
#2102 isolate ltr/gag RNA was denatured and allowed to
dimerize in the presence or absence of ONs, including LNA/
DNA mix-mers (Fig. 2A). The RNA 9-mer asDIS 1 reduced
dimer formation by 61% compared to no ON, while the
DNA 9-mer asDIS 2 only induced 14% reduction (Fig. 2B).
By exchanging three DNA bases (1 + 2) to LNA at the ends
of the DNA 9-mer (asDIS 3), the inhibitory capacity was en-
hanced to the levels of the RNA ON (asDIS 1), 62% reduction.asDIS 4 with seven exchanged bases and asDIS 5, all LNA, re-
duced dimerization with 42% and 45%, respectively. The sense
9-mer sDIS 6 reduced the dimerization with 50% compared to
the sample without ON.
LNA/DNA mix-mers activate RNase H mediated RNA
cleavage. The 630 nucleotide in vitro transcribed #2102
RNA was incubated with RNase H and the diﬀerent ONs.
The DIS target region is located roughly in the middle of the
transcript and RNase H digestion at the target site would gen-
erate two cleavage products of around 260 and 370 nucleo-
tides, depending on where the DNA is located in the ON
(Fig. 2C). Incubation with RNase H but without ON did not
mediate cleavage and showed the full-length transcript only
(Fig. 2D, no ON). The RNA transcript incubated with RNase
H and the DNA antisense 9-mer asDIS 2 generated the two ex-
pected bands, while the RNA ON asDIS 1 did not activate
RNase H. RNase H was also activated by the antisense
LNA/DNA mix-mer asDIS 3, containing six consecutive
DNA bases. asDIS 4 and asDIS 5 antisense 9-mers containing
two consecutive and no DNA bases, respectively, did not
activate RNase H. The sense 9-mer sDIS 6 did not activate
RNase H.
Fig. 3. 18-mer performance. (A) Inhibition of in vitro dimerization by
diﬀerent 18-mer ONs in analogy with Fig. 2B. Mean and standard
deviation are from two to three replicates (\P < 0.05, \\P < 0.01 and
\\\P < 0.001, as compared to mismatch control asDIS 7 mm). (B)
RNase H activation by diﬀerent 18-mer ONs as in Fig. 2D.
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LNA/DNA 18-mers contained either 3 0 or 5 0 nine nucleo-
tides long DNA tails while keeping the 9 bases covering the
DIS loop constant as in the 9-mers asDIS 4 or sDIS 6. The
nine nucleotide DNA tail should be suﬃcient for activating
RNase H, while the loop spanning nine bases should give
strong binding.
The dimerization inhibition using the 18-mers was per-
formed as with the 9-mers. The antisense 18-mers asDIS 8
and asDIS 9, with 3 0- and 5 0 DNA tail, respectively, reduced
dimer formation with 59% and 54% (Fig. 3A). They performed
slightly better than the corresponding sense ONs (sDIS 10 and
sDIS 11), which showed 36% and 40% reduction, respectively.
asDIS 8, with 59% reduction, was similar in performance to
the 9-mers asDIS 1 and asDIS 3. The mismatch control asDIS
7 mm corresponding to asDIS 8 did not show noteworthy inhi-
bition (10% reduction).
In the case of RNase H activation, the antisense 18-mers as-
DIS 8 and asDIS 9 activated RNase H, whereas sDIS 10 and
sDIS 11 did not (Fig. 3B). There was, however, weak non-spe-ciﬁc cleavage with sDIS 10 as well as with asDIS 9. The mis-
match control asDIS 7 mm also showed non-speciﬁc activation.
3.3. Receptor-mediated transfection
Delivering mix-mers by receptor-mediated transfection
showed high percentage of uptake, a prerequisite for antisense
ON inhibition of HIV replication. PEI condenses and protects
the ON, while the transferrin binds CD-71 (transferrin recep-
tor, on T-cells for example) and causes receptor-mediated
endocytosis. The transfected ONs were taken up by most Jur-
kat-Tat cells and accumulated in the endosomal compartments
(Fig. 4A). ONs could be detected up to eight days in some cells
(data not shown). Other commercial transfection agents,
including PEI, were also tried. However, all gave low percent-
age of transfection even though in some cases the few transfec-
ted cells displayed more ONs per cell (i.e., stronger ﬂuorescent
signal) (data not shown).3.4. Inhibition of virus replication
LNA/DNA mix-mers inhibit HIV-1 replication. The anti-
sense 18-mer with a 3 0 DNA tail asDIS 8 had a clear eﬀect
in inhibiting the HIV replication. HIV-1 RT activity was re-
duced with 64% compared to untreated cells (Fig. 4B). HIV-
1 inhibition by asDIS 8 was initially seen by ELISA detecting
the HIV-1 p24 antigen (data not shown). asDIS 9 and sDIS 10
reduced the virus production with 33% and 50%, respectively.
The sense ON sDIS 11 surprisingly displayed a 59% reduction.
The mismatch control (asDIS 7 mm) slightly aﬀected the virus
production. The 9-mers did not inhibit virus replication per se
(data not shown).4. Discussion
The current study shows the beneﬁt of the nucleotide analog
LNA in a biological context and is the ﬁrst study that demon-
strates that the HIV-1 dimerization site is a potential antisense
target that can combat the virus replication. This is of impor-
tance for implication of the LNA/DNA mix-mer technology in
development of antisense therapeutics against HIV-1 and other
diseases.
Here, we have shown that high aﬃnity antisense LNA/DNA
mix-mers enhance inhibition of HIV dimerization and that
they can induce RNase H degradation of the target RNA. In
addition, the LNA modiﬁcation promotes stability but not
toxicity [7]. To deliver the ONs, we have employed a recep-
tor-mediated transfection system, which may be clinically
applicable and has given a good uptake in the transfected T-
cell line.
LNA has high binding aﬃnity to RNA [4,30]. The antisense
RNA 9-mer asDIS 1 showed inhibition and the corresponding
DNA asDIS 2 did not, as has been shown previously [22].
When exchanging three ﬂanking DNA nucleotides (one 5 0
and two 3 0) bases for LNA (asDIS 3), the same potent inhibi-
tory eﬀect as with the RNA was seen. These results showed
that it was indeed possible to confer DNA ON with better
DIS targeting properties by including the enhanced binding
capacity of LNA. Further increase in the LNA content (asDIS
4 and asDIS 5) also showed improved dimerization inhibitory
eﬀects compared to DNA alone. Interestingly, but not surpris-
ingly, the sense LNA/DNA mix-mer (sDIS 6) also had a good
inhibitory eﬀect. DIS is self-complementary and the dimeriza-
Fig. 4. (A) Receptor mediated delivery of FITC labeled LNA/
phosphorothioate mix-mer to Jurkat-Tat cells. FITC has a green
color and the DAPI nuclear stain is blue. Uptake in close to 100% of
the cells is shown (low magniﬁcation). FITC labeled oligonucleotides
are accumulated in endosomal compartments (high magniﬁcation). (B)
Inhibition of HIV replication by 18-mer LNA/DNA mix-mers. The
amount of reverse transcriptase in cell supernatants was measured
seven days post infection by reverse transcriptase activity assay. Mean
and standard deviation are from two separate experiments, each in
which three to four separate infections per oligonucleotide were made
(*P < 0.05, **P < 0.01 and ***P < 0.001, as compared to mismatch
control asDIS 7 mm).
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Hence, the sense ON can bind DIS and there are indications
that sense ONs work as competitive inhibitors to the dimeriza-
tion process [22,23].
In the RNase H assays asDIS 3, the LNA/DNA mix-mer
with a 6 DNA nucleotide window, activated RNase H medi-
ated cleavage as eﬀectively as the DNA ON (asDIS 2). Thisis in analogy with previous studies [7,10,31]. Kurreck et al.
showed that eight consecutive DNA bases in an LNA/DNA
mix-mer antisense ON give full RNase H activation, even
though six bases will still be suﬃcient to induce activation.
Shen et al. have shown that four consecutive DNA bases acti-
vate RNase H even if there is a nucleotide mismatch [32].
The antisense 18-mer with a 3 0 DNA tail, asDIS 8, was a
good inhibitor of dimerization and a good activator of RNase
H. asDIS 8 subsequently also inhibited HIV-1 replication. The
sense version sDIS 11 was also a good inhibitor of virus repli-
cation without activating RNase H. This is in accordance with
the discussion concerning the sense 9-mer sDIS6. HIV genome
has two RNA sense strands coming together in the dimeriza-
tion process. The 18-mer sense ON sDIS 11 can pair to DIS
and likely function as a competitive inhibitor to the dimeriza-
tion process. The sense ON sDIS 10 also showed a slight
downregulation of HIV-1 replication. Even though asDIS 9
inhibited in vitro dimerization and activated RNase H, it
was not an eﬃcient ON in inhibiting HIV-1 replication. This
indicates that target site availability also may be diﬀerent in vi-
tro and in vivo for the diﬀerent ONs. Seemingly, inhibition of
dimerization is necessary for HIV-1 downregulation of virus
replication when targeting DIS, while RNase H activation is
not. Hence, interruption of the natural HIV-1 genome process-
ing is more important than targeting the genome for RNase H
degradation when targeting DIS. RNase H also induced some
non-speciﬁc target cleavage for some of the 18-mers, which
also might contribute to reduce speciﬁcity. Additionally, we
believe that the seen inhibition of virus replication is due to
antisense eﬀects and exclude side-eﬀects like cytotoxicity. Nei-
ther the ‘‘no ON’’ nor the mismatch control (asDIS 7 mm)
inhibited virus replication, which indicates that there are no
side-eﬀects due to the presence of control ON per se that cause
inhibition of virus replication. The ONs have also been
checked for immunostimulatory CpG motifs, which could
interfere and there are none.
The 9-mer ONs did not inhibit HIV replication (data not
shown). This could be due to unspeciﬁc binding of the ONs
to cellular RNA molecules and might not play a practical role
for cell culture or in vivo use.
We have relative modest inhibitory eﬀects on HIV replica-
tion. However, this is performed with a clinical HIV-1 subtype
A isolate, not adapted for assaying and replication in a T-cell
line. The target has been cloned from this isolate and adapted
for evaluation in vitro and ﬁnally tested for virus replication,
with the objective to use materials as close to clinical relevance.
The ON concentration used (160 nM) is also very low. This
makes the LNA/DNA mix-mers competitive also to siRNA.
For example, the SARS virus replication is inhibited by siRNA
in the 100 nM range [33].
The mix-mer design from this study could be used to target
other important secondary structures along with other eﬃcient
antisense targets like trans-activating region (TAR), which has
in vitro been successfully targeted with LNA mix-mers [34,35].
In conclusion, introduction of LNA improves antisense inhibi-
tion of HIV-1 dimerization. A stretch of six consecutive DNA
bases in an LNA/DNA mix-mer is necessary and suﬃcient to
activate RNase H degradation of the target RNA. Receptor-
mediated transfection is suitable for ON delivery to a T-cell
line and the LNA/DNA mix-mers are capable of inhibiting
HIV-1 replication at low concentrations. We hope these data
would stimulate the introduction of LNA/DNA mix-mer
290 J. Elme´n et al. / FEBS Letters 578 (2004) 285–290technology against HIV in in vivo models and possibly in
clinical settings.
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